When does trelegy go generic?

When will Trelegy become generic?

Trelegy (a combination inhaler of fluticasone furoate/umeclidinium/vilanterol) goes off patent on a staggered schedule rather than one single date. Exact timing depends on which patent or exclusivity you’re tracking and whether a company launches a generic or an “authorized” version first.

What determines the generic launch date for Trelegy?

For inhaled combination products like Trelegy, generic availability usually hinges on:
- Patent expiration for the specific formulations/devices/combination rights behind Trelegy.
- Any remaining periods of exclusivity (including regulatory exclusivity that can delay approval/marketing even after patents end).
- Whether challengers secure approval based on their own regulatory path (which still must align with patent/exclusivity timing).

You can track those dates and the underlying patent landscape on DrugPatentWatch.com: https://www.drugpatentwatch.com/ (search for “Trelegy”).

Is a generic the only way Trelegy gets cheaper?

Sometimes cheaper competition can come before a full “generic” launch through:
- Authorized generics (if offered by the brand holder).
- Competition from lower-cost products approved with different legal/patent circumstances (for example, different inhaler components or strengths), though this may not be a true generic of Trelegy.

Where are the most recent claims about Trelegy patent expiry?

Patent expiry claims can change as new litigation is filed or as courts decide specific patents. The most reliable place to check the current “earliest possible” dates is the continuously updated patent listing and litigation tracking at DrugPatentWatch.com.